Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...

Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in ...

To properly understand Exelixis' profit results, we need to consider the US$85m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance ...

ALAMEDA, Calif., February 20, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...